What is the appropriate starting dose of Crestor (rosuvastatin) for a 59-year-old female patient with hyperlipidemia, characterized by elevated total cholesterol, low-density lipoprotein (LDL) cholesterol of 153, triglycerides of 123, and high-density lipoprotein (HDL) cholesterol of 47?

Starting Dose of Rosuvastatin for a 59-Year-Old Female with Hyperlipidemia

Start rosuvastatin 10 mg once daily for this patient, as her LDL-C of 153 mg/dL requires pharmacotherapy and this dose will achieve her treatment goal of LDL-C <100 mg/dL in the majority of patients.

Risk Stratification and Treatment Goals

This patient requires immediate assessment of her 10-year cardiovascular risk to determine the appropriate LDL-C target:

• If 10-year CHD risk is 10-20%: LDL-C goal is <130 mg/dL, and pharmacotherapy is indicated when LDL-C ≥130 mg/dL after lifestyle modifications 1, 2
• If 10-year CHD risk is >20% or has diabetes/CHD equivalent: LDL-C goal is <100 mg/dL, and statin therapy should be initiated simultaneously with lifestyle changes 1, 2
• Optimal lipid targets for women: LDL-C <100 mg/dL, HDL-C >50 mg/dL (her HDL of 47 is slightly below target), triglycerides <150 mg/dL (her level of 123 is acceptable), and non-HDL-C <130 mg/dL 1, 2

Rationale for 10 mg Starting Dose

Rosuvastatin 10 mg is the appropriate starting dose because:

• The FDA-approved dosage range is 5-40 mg once daily, with the recommended dose depending on LDL-C level and cardiovascular risk 3
• Rosuvastatin 10 mg reduces LDL-C by approximately 43-52% in most patients 4, 5
• With her baseline LDL-C of 153 mg/dL, a 45% reduction would bring her to approximately 85 mg/dL, well below the <100 mg/dL goal 4
• Starting at 10 mg rather than 5 mg ensures more patients reach their LDL-C goal without requiring dose titration 5, 6
• Rosuvastatin 10 mg enables 66-73% of high-risk patients to achieve LDL-C <100 mg/dL, compared to only 42% with atorvastatin 10 mg 6

Dosing Considerations

Important patient-specific factors:

• No dose adjustment needed for this patient as she has no documented renal impairment, is not Asian, and is not on interacting medications 3
• If she were Asian: Start at 5 mg once daily due to increased rosuvastatin plasma concentrations 3
• If severe renal impairment (CrCl <30 mL/min): Start at 5 mg once daily and do not exceed 10 mg daily 3

Administration Instructions

• Take rosuvastatin once daily at any time of day, with or without food 3
• Swallow tablets whole 3
• If taking aluminum/magnesium hydroxide antacids, administer rosuvastatin at least 2 hours before the antacid 3
• Reassess lipid panel in 4-12 weeks to evaluate response and adjust dose if needed 3, 7

Concurrent Lifestyle Modifications (Essential)

Even with statin initiation, aggressive lifestyle changes must be implemented simultaneously:

• Dietary fat modification: Reduce saturated fat to <7% of total calories, cholesterol to <200 mg/day, and trans-fatty acids to <1% of energy 1, 2, 8
• Increase beneficial nutrients: Add 2 g/day plant sterols/stanols and 10-25 g/day viscous fiber 7, 8
• Omega-3 fatty acids: Consume fish twice weekly or consider 850-1000 mg EPA/DHA supplementation 1, 2
• Physical activity: At least 30 minutes of moderate-intensity exercise on most days 1, 2, 8
• Weight management: Target BMI 18.5-24.9 kg/m² and waist circumference <35 inches 1, 2, 8

These lifestyle modifications alone can reduce LDL-C by 23% and total cholesterol by 23% within 2-3 weeks, but given her current LDL-C level, pharmacotherapy should not be delayed 9.

Monitoring Plan

• Lipid panel at 4-12 weeks: Assess LDL-C response and adjust dose if not at goal 3, 7
• If LDL-C remains >100 mg/dL: Increase to rosuvastatin 20 mg daily 3
• Monitor for adverse effects: Check for myalgia, liver function abnormalities (rare with rosuvastatin), though routine monitoring is not required unless symptomatic 5
• Long-term monitoring: Reassess lipid profile every 6-12 months once at goal 10

Common Pitfalls to Avoid

• Do not start at 5 mg unless the patient is Asian, has severe renal impairment, or is on specific interacting medications—this underdoses most patients and delays goal achievement 3, 6
• Do not delay statin therapy for a prolonged trial of lifestyle changes alone when LDL-C is ≥160 mg/dL or patient is high-risk—guidelines support simultaneous initiation 1, 2
• Do not neglect lifestyle modifications once statin is started—these remain essential for optimal cardiovascular risk reduction 1, 2, 8